Barco Al-Iraq and PATHFAST®: Redefining Urgent Diagnostics in Iraq

Barco Al-Iraq is proud to announce its exclusive partnership with PATHFAST®, a next-generation diagnostic platform developed by LSI Medience Corporation – Japan. This strategic collaboration brings cutting-edge point-of-care technology to Iraq, enabling healthcare professionals to deliver rapid, accurate, and laboratory-quality results where and when they are needed most.
PATHFAST® is powered by magnetic particle chemiluminescence technology (MPCL), providing high-sensitivity and specificity in just a few minutes. With its compact design and minimal sample requirements, it integrates seamlessly into emergency departments, intensive care units, and other critical care settings. Its assays are FDA-approved and CE-marked, ensuring global quality standards.
Renowned for its high-sensitivity troponin I testing, PATHFAST® also offers a focused panel of essential biomarkers, including NT-proBNP, D-dimer, hsCRP, CK-MB, myoglobin, and procalcitonin. This allows clinicians to make fast, confident decisions in diagnosing cardiac events, infections, inflammation, and other time-sensitive conditions.
Through this partnership, Barco Al-Iraq reinforces its commitment to advancing diagnostic capabilities across Iraq by introducing trusted global innovations that support better patient outcomes and more efficient clinical workflows
PHC Holdings Corporation